Gastroschisis is a rare, life-threatening and debilitating birth abnormality in late preterm infants where the infant is born with externalized intestines.
After the initial surgical repair, gastroschisis represents an area of significant unmet medical need with no definitive treatment available. Post-operative management of gastroschisis is largely aimed at overcoming the significant morbidity related to the reduction in gut motility and consequent feeding intolerance necessitating the prolonged requirement for parenteral nutrition. Infants suffering from gastroschisis have a greatly increased risk of sepsis and liver cholestasis. It is common for neonates born with gastroschisis to have typically an extended hospital stay of 1-5 months thereby causing significant burden to the healthcare system.
The active bacteria used in IBP-1016 is known to enhance gut motility and function in infants with feeding intolerance.